Abbott Laboratories (ABT) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABT Analyst Ratings

Strong Buy

15 Buy

1 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Abbott

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

CHF109.58

▲(28.16% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is CHF109.58 with a high forecast of CHF125.76 and a low forecast of CHF97.11. The average price target represents a 28.16% change from the last price of CHF85.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"86":"CHF86","96":"CHF96","106":"CHF106","116":"CHF116","126":"CHF126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125.76023272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF125.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":109.5785521428,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF109.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.10600248,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF97.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[86,96,106,116,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89,91.82771020923077,94.65542041846155,97.4831306276923,100.31084083692308,103.13855104615385,105.96626125538462,108.7939714646154,111.62168167384615,114.44939188307693,117.2771020923077,120.10481230153846,122.93252251076925,{"y":125.76023272,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89,90.58296554944616,92.16593109889232,93.74889664833846,95.33186219778462,96.91482774723077,98.49779329667693,100.08075884612308,101.66372439556923,103.24668994501539,104.82965549446155,106.4126210439077,107.99558659335385,{"y":109.5785521428,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89,89.62353865230769,90.24707730461539,90.87061595692307,91.49415460923078,92.11769326153846,92.74123191384615,93.36477056615385,93.98830921846154,94.61184787076922,95.23538652307693,95.85892517538461,96.48246382769231,{"y":97.10600248,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":91.756,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.756,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.508,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.508,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.508,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.014,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.014,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.014,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.488,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.498,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.498,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF125.76

Average Price TargetCHF109.58

Lowest Price TargetCHF97.11

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Danielle Antalffy

UBS

CHF125.76

Buy

47.09%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Kura Oncology (NASDAQ: KURA)

Joanne Wuensch

Citi

CHF111.43→CHF108.25

Buy

26.61%

Upside

Assigned

03/12/26

Abbott price target lowered to $136 from $140 at CitiAbbott price target lowered to $136 from $140 at Citi

Marie Thibault

BTIG

CHF111.43

Buy

30.33%

Upside

Reiterated

02/18/26

BTIG Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Josh Jennings

TD Cowen

CHF109.05

Buy

27.54%

Upside

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX) and Abbott Laboratories (NYSE: ABT)

Adam Maeder

Piper Sandler

CHF107.45

Buy

25.68%

Upside

Reiterated

02/06/26

Piper Sandler Sticks to Its Buy Rating for Abbott Laboratories (ABT)

Matt Miksic

Barclays

CHF113.03

Buy

32.19%

Upside

Reiterated

02/03/26

Analysts Are Bullish on These Healthcare Stocks: Qiagen (QGEN), Abbott Laboratories (ABT)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Maze Therapeutics, Inc. (NASDAQ: MAZE)

Suraj Kalia

Oppenheimer

CHF111.43→CHF105.07

Buy

22.88%

Upside

Reiterated

01/23/26

Abbott price target lowered to $132 from $140 at OppenheimerAbbott price target lowered to $132 from $140 at Oppenheimer

Matthew Taylor

Jefferies

CHF115.41

Buy

34.99%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and CVRx (NASDAQ: CVRX)

Anthony Petrone

Mizuho Securities

CHF111.43→CHF99.49

Hold

16.37%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $140 at MizuhoAbbott price target lowered to $125 from $140 at Mizuho

Larry Biegelsen

Wells Fargo

CHF116.21→CHF97.11

Buy

13.57%

Upside

Reiterated

01/23/26

Abbott price target lowered to $122 from $146 at Wells FargoAbbott price target lowered to $122 from $146 at Wells Fargo

Vijay Kumar

Evercore ISI

CHF114.62→CHF109.84

Buy

28.47%

Upside

Reiterated

01/23/26

Evercore ISI Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Lee Hambright

Bernstein

CHF122.58→CHF99.49

Buy

16.37%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $154 at BernsteinAbbott price target lowered to $125 from $154 at Bernstein

Shagun Singh Chadha

RBC Capital

CHF117→CHF107.45

Buy

25.68%

Upside

Reiterated

01/22/26

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), BioCryst (BCRX)

Travis Steed

Bank of America Securities

CHF119.39

Buy

39.64%

Upside

Reiterated

01/19/26

Bank of America Securities Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Danielle Antalffy

UBS

CHF125.76

Buy

47.09%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Kura Oncology (NASDAQ: KURA)

Joanne Wuensch

Citi

CHF111.43→CHF108.25

Buy

26.61%

Upside

Assigned

03/12/26

Abbott price target lowered to $136 from $140 at CitiAbbott price target lowered to $136 from $140 at Citi

Marie Thibault

BTIG

CHF111.43

Buy

30.33%

Upside

Reiterated

02/18/26

BTIG Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Josh Jennings

TD Cowen

CHF109.05

Buy

27.54%

Upside

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX) and Abbott Laboratories (NYSE: ABT)

Adam Maeder

Piper Sandler

CHF107.45

Buy

25.68%

Upside

Reiterated

02/06/26

Piper Sandler Sticks to Its Buy Rating for Abbott Laboratories (ABT)

Matt Miksic

Barclays

CHF113.03

Buy

32.19%

Upside

Reiterated

02/03/26

Analysts Are Bullish on These Healthcare Stocks: Qiagen (QGEN), Abbott Laboratories (ABT)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Maze Therapeutics, Inc. (NASDAQ: MAZE)

Suraj Kalia

Oppenheimer

CHF111.43→CHF105.07

Buy

22.88%

Upside

Reiterated

01/23/26

Abbott price target lowered to $132 from $140 at OppenheimerAbbott price target lowered to $132 from $140 at Oppenheimer

Matthew Taylor

Jefferies

CHF115.41

Buy

34.99%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and CVRx (NASDAQ: CVRX)

Anthony Petrone

Mizuho Securities

CHF111.43→CHF99.49

Hold

16.37%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $140 at MizuhoAbbott price target lowered to $125 from $140 at Mizuho

Larry Biegelsen

Wells Fargo

CHF116.21→CHF97.11

Buy

13.57%

Upside

Reiterated

01/23/26

Abbott price target lowered to $122 from $146 at Wells FargoAbbott price target lowered to $122 from $146 at Wells Fargo

Vijay Kumar

Evercore ISI

CHF114.62→CHF109.84

Buy

28.47%

Upside

Reiterated

01/23/26

Evercore ISI Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Lee Hambright

Bernstein

CHF122.58→CHF99.49

Buy

16.37%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $154 at BernsteinAbbott price target lowered to $125 from $154 at Bernstein

Shagun Singh Chadha

RBC Capital

CHF117→CHF107.45

Buy

25.68%

Upside

Reiterated

01/22/26

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), BioCryst (BCRX)

Travis Steed

Bank of America Securities

CHF119.39

Buy

39.64%

Upside

Reiterated

01/19/26

Bank of America Securities Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months

xxx

Success Rate

16/20 ratings generated profit

Average Return

+4.05%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +4.05% per trade.

1 Year

Jayson BedfordRaymond James

Success Rate

36/45 ratings generated profit

Average Return

+17.78%

reiterated a buy rating 5 months ago

Copying Jayson Bedford's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +17.78% per trade.

2 Years

xxx

Success Rate

15/20 ratings generated profit

Average Return

+31.24%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +31.24% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABT has received 37 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 109.58.

Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is CHF0.91 with a range of CHF0.89 to CHF0.93. The previous quarter’s EPS was CHF1.18. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is CHF8.64B with a range of CHF8.40B to CHF8.79B. The previous quarter’s sales results were CHF9.00B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Stock Forecast FAQ

What is CH:ABT’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 109.58.

What is CH:ABT’s upside potential, based on the analysts’ average price target?

Abbott Laboratories has 28.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Abbott Laboratories a Buy, Sell or Hold?

Abbott Laboratories has a consensus rating of Strong Buy, which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.

What is Abbott Laboratories’s share price target?

The average share price target for Abbott Laboratories is 109.58. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF125.76 ,and the lowest forecast is CHF97.11. The average share price target represents 28.16% Increase from the current price of CHF85.5.

What do analysts say about Abbott Laboratories?

Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Abbott Laboratories?

To buy shares of CH:ABT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Abbott Laboratories (ABT) Stock Forecast & Price Target

ABT Analyst Ratings

ABT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abbott Laboratories

ABT Analyst Recommendation Trends

ABT Financial Forecast

ABT Earnings Forecast

ABT Sales Forecast

ABT Stock Forecast FAQ

Detailed List of Analyst Forecasts